Savant Capital LLC Invests $2.26 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Savant Capital LLC purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 16,543 shares of the company’s stock, valued at approximately $2,258,000.

A number of other large investors also recently bought and sold shares of the business. State Street Corp increased its stake in Neurocrine Biosciences by 11.7% in the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after buying an additional 539,936 shares during the period. Jennison Associates LLC raised its stake in shares of Neurocrine Biosciences by 145.1% during the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock valued at $112,025,000 after acquiring an additional 485,894 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 639.6% in the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after purchasing an additional 363,863 shares during the period. Braidwell LP grew its stake in Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock worth $105,734,000 after purchasing an additional 158,665 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Neurocrine Biosciences by 23.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 533,324 shares of the company’s stock worth $61,450,000 after purchasing an additional 102,715 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Activity

In other news, CEO Kyle Gano sold 65,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00. Following the sale, the chief executive officer now owns 135,392 shares in the company, valued at $19,157,968. This represents a 32.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kevin Charles Gorman sold 146,105 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the transaction, the director now directly owns 514,596 shares of the company’s stock, valued at approximately $76,911,518.16. This trade represents a 22.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 226,647 shares of company stock valued at $33,186,271. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Trading Up 0.3 %

Shares of Neurocrine Biosciences stock opened at $117.18 on Thursday. The firm’s 50 day simple moving average is $138.49 and its two-hundred day simple moving average is $131.02. The firm has a market capitalization of $11.86 billion, a price-to-earnings ratio of 35.62 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. On average, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Analyst Ratings Changes

NBIX has been the subject of several research reports. Wedbush lowered their target price on Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a report on Friday, February 7th. BMO Capital Markets cut their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Monday. HC Wainwright dropped their price objective on shares of Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Royal Bank of Canada reduced their price objective on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating for the company in a research note on Friday, February 7th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.